Mesenchymal stromal cells for treatment of the acute respiratory distress syndrome: The beginning of the story. (November 2015)

• Record Type: Journal Article
• Authors: Morrison, T; McAuley, DF; Krasnodembskaya, A
• Is Part Of: Journal of the Intensive Care Society. Volume 16:Number 4(2015:Nov.)
• Page Start: 320
• Page End: 329
• Publication Date: 2015-11
• Subjects: Acute respiratory distress syndrome -- mesenchymal stromal cells; Critical care medicine -- Periodicals; Intensive care units -- Periodicals; 616.028
• DOI: 10.1177/1751143715586420
• Languages: English
• ISSNs: 1751-1437

Abstract

In spite of decades of research, the acute respiratory distress syndrome (ARDS) continues to have an unacceptably high mortality and morbidity. Mesenchymal stromal cells (MSCs) present a promising candidate for the treatment of this condition and have demonstrated benefit in preclinical models. MSCs, which are a topic of growing interest in many inflammatory disorders, have already progressed to early phase clinical trials in ARDS. While a number of their mechanisms of effect have been elucidated, a better understanding of the complex actions of these cells may pave the way for MSC modifications, which might enable more effective translation into clinical practice.